NASDAQ · CRMD

CorMedix Inc.

$7.60 -$0.27 (-3.43%) 1D After hours

Key Metrics

$617.42M
Market cap
3.41×
P/E · TTM
$400.05M
Revenue · TTM
$181.01M
Net income
EPS · TTM $2.62
Dividend yield
Free cash flow $194.71M
Beta · 1Y 1.20
EBITDA · TTM $196.13M
Gross margin 85.8%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Mar 5
    The stock moved -11.5% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 5

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$617.42M
Enterprise value
Shares outstanding78.5M
52-wk range$6.13 – $14.96
Avg volume · 20D981.5K
Net cash
Book value / share$6.34
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About CorMedix Inc.
IPO dateMay 13, 2010
Employees191

Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E3.41
P/S1.54
P/FCF3.17
EV/EBITDA
EV/Sales
Graham №$19.34

Profitability

Gross 85.8%
Operating 46.2%
Net 45.2%
FCF 48.7%
ROE / ROIC 69.4% · 69.4%

Financial Health

Current ratio2.98
Quick ratio2.74
Debt / equity
Debt / EBITDA
Net cash
Working capital$254.34M

Cash Flow · TTM

Operating CF $197.69M
Capex −$2.98M
Free cash flow $194.71M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

5 / 9
Middling fundamentals · 5 of 9 signals passing

Altman Z-Score

2.4
Grey zone (1.81–2.99) · monitor

Graham Number vs Price

$19.34 vs $7.60
Trades below classic defensive value — Graham-cheap
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings